Method of reducing MACE in diabetic patients subsequent to stent placement
US-9217042-B2 · Dec 22, 2015 · US
US9867905B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9867905-B2 |
| Application number | US-33208408-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2008 |
| Priority date | Dec 10, 2007 |
| Publication date | Jan 16, 2018 |
| Grant date | Jan 16, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Collagen based-matrices and methods of their use are described. More particularly, collagen-based matrices for differentiating stem cells and progenitor cells, and for producing and isolating blood vessels and vascularized graft constructs are described.
Opening claim text (preview).
What is claimed is: 1. A tissue graft composition, said composition comprising: an engineered, purified collagen-based matrix comprising collagen fibrils, wherein the matrix has a collagen fibril microstructure including fibril-fibril branching; and a network of lumenized, endothelial cell-lined vessels formed in vitro, said vessels capable of persisting for more than 7 days in vitro; wherein said collagen fibrils are polymerized from a pig skin collagen source comprising a mixture of type I collagen monomers and oligomers, wherein the concentration of collagen in the polymerization reaction is 0.3 mg/ml to 1 mg/ml, wherein the vessels are formed from endothelial progenitor cells, and wherein the matrix has a shear storage modulus of 40 Pa to 50 Pa and a fibril volume fraction of 5% to 10%; and wherein the tissue graft composition is produced by engineering the purified collagen-based matrix, and seeding the matrix at a density of 1×10 5 to 5×10 5 endothelial progenitor cells per milliliter to form one or more vessels within the matrix. 2. The tissue graft composition of claim 1 , wherein said matrix has a loss modulus of from about 1 Pa to about 75 Pa. 3. The tissue graft composition of claim 1 , wherein said matrix has a compression modulus of 2,500 Pa to about 18,000 Pa.
for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062) · CPC title
Collagen · CPC title
Endothelial cells · CPC title
Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title
Stem cells · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.